Targovax Key Opinion Leader Symposium on Oncolytic Viruses in New York City today, 11 October, 2018
Symposium faculty to include Dmitriy Zamarin, MD, PhD, and Alexander N.
Shoushtari, MD, medical oncologists from Memorial Sloan Kettering Cancer Center
Oslo, Norway, 11 October 2018 - Targovax ASA (OSE: TRVX), a clinical stage
biotechnology company developing immune activators to target hard to treat solid
tumors, is hosting a Key Opinion Leader (KOL) symposium in New York City today,
featuring two renowned immunotherapy experts from the Memorial Sloan Kettering
Cancer Center.
The meeting will consist of presentations from world leading experts on
oncolytic viruses, as well as presentations from the Targovax senior management
team. Presentations and discussion will include an overview of oncolytic viruses
in general and the potential of this emerging technology in the treatment of
cancer, including how the engineered ONCOS adenovirus fits into the broader
landscape
The event starts at 12:00 EST / 18:00 CET.
Agenda:
12:00 - 12:10: Welcome remarks, Øystein Soug, CEO, Targovax
12:10 - 12:50: Oncolytic virus overview, Dr. Dmitriy Zamarin
12:50 - 13:30: Melanoma: the disease, CPIs, and lack of treatment options; Early
ONCOS-102 data,
Dr. Alexander Shoushtari
13:30 - 13:50: Mesothelioma ORR data, Dr. Magnus Jäderberg, CMO, Targovax
Symposium Faculty participants:
Dmitriy Zamarin, MD, PhD, Medical Oncologist, Memorial Sloan Kettering
Dr. Zamarin’s research is focused on the development of novel ways to use the
immune system to treat cancer, including evaluation of novel immunotherapy
drugs. He has published several landmark papers on oncolytic viruses and is the
Study Chair on the ONCOS-102 trial in peritoneal cancer, in collaboration with
Cancer Research Institute (CRI), Ludwig Cancer Research and
MedImmune/AstraZeneca.
Alexander N. Shoushtari, MD, Medical Oncologist, Memorial Sloan Kettering
Dr. Shoushtari is a renowned expert in melanoma, with a research focus on uveal
and mucosal melanomas. He has been part of several immunotherapy trials at MSKCC
and is the Principal Investigator on the ONCOS-102 phase I trial in CPI
refractory advanced melanoma.
Drs. Zamarin and Shoushtari are both members of the research team of Dr. Jedd
Wolchok, MD, PhD, Chief, Melanoma and Immunotherapeutics Service at the Memorial
Sloan Kettering Cancer Center.
A live webcast of the symposium will be available in the Events and
Presentations section of the Targovax website. .
To register for the event, please contact [email protected] or visit
www.troutaccess.com.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: [email protected]
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: [email protected]
Simon Conway/Stephanie Cuthbert - FTI Consulting (International)
Phone: +44 20 3727 1000
Email: [email protected]
About Targovax
Activating the patient’s immune system to fight cance
Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune
activators to target hard to treat solid tumors. Immuno-oncology is currently
one of the fastest growing therapeutic fields in medicine.
Targovax’s lead product candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect and
replicate in cancer cells. It is used as a therapeutic cancer vaccine and has
been shown to activate the immune system to generate tumor-specific immune
responses. In phase I trials, ONCOS-102 induced both local and systemic innate
and adaptive immune activation, which has been associated with clinical benefit.
ONCOS-102’s lead indication is mesothelioma, where the virus is currently being
tested in a randomized phase II trial, with a phase Ib safety lead-in cohort.
Another trial, in advanced melanoma, is expected to produce important proof of
concept data for checkpoint inhibitor refractory patients within the next 6-12
months.
Targovax is also developing a neo-antigen cancer vaccine targeting tumors that
express mutated forms of RAS - mutations known to drive cancer. The TG vaccine
program has shown a signal of efficacy in a 32-patient trial with TG01 in
resected pancreatic cancer. A next generation product candidate, TG02 is
currently tested as monotherapy and will also be tested in combination with
Keytruda® (an anti-PD1 Check p
Ekstern link: http://www.newsweb.no/index.jsp?messageId=461051
Nyheten er levert av OBI.